Six months after Congress voted for site-neutral Medicare payments, lawmakers appear ready to carve out loopholes.
As hospital margins on traditional fee-for-service Medicare patients plunged deeper into the red, cost-cutting at hospitals has allowed many to make up those losses from their commercially insured clientele.
The Medicare Payment Advisory Commission has completed work on a road map for overhauling how the program pays for post-acute care. The advisory panel voted to back a variety of changes to the Part D prescription drug program that could save as much as $10 billion over five years.
As conversations in healthcare continue to focus on quality, patient safety and a system shifting to value over volume, Modern Healthcare's 12th annual ranking of the 50 Most Influential Physician Executives and Leaders increasingly reflects the industry players charged with making it happen.
Medicare's plans to overhaul the way it reimburses doctors and hospitals for the more than $20 billion worth of outpatient drugs they administer each year has sharply divided the provider community. The fault lines roughly align with the stakes in the status quo.
New York-based Royalty Pharma has paid $1.14 billion for a portion of the future sales of Xtandi, a prostate cancer drug.
MedPAC is wrapping up work on a report that outlines a unified payment system for post-acute care settings. The panel will vote on a formal report next month. It also plans to suggest the CMS accelerate its timeline of when the new pay scheme will see the light of day.
The most interesting thing about the preliminary rate notice for 2017 Medicare Advantage plans may be what federal policymakers left out. The thick document made no mention of health-risk assessments, which surprised the industry.
A new federal proposal would slash overpayments made to Medicare Advantage plans sponsored by employers and unions years after an advisory board recommended the policy.
The Medicare Payment Advisory Commission has backed a proposal to reduce Part B drug payment rates for hospitals participating in the 340B Drug Pricing Program, though members had signaled they would oppose it.
Congress is likely to take up a measure in the new year that would exempt hospital outpatient departments currently under construction from a “site-neutral” Medicare payment provision, which made it into the two-year budget deal in October that avoided a potential default on the...
The Medicare Payment Advisory Commission is starting the complex work of balancing quality of patient care with building a prototype that may change how Medicare reimburses skilled-nursing facilities, home health agencies, inpatient rehabilitation facilities and long-term-care hospitals.